Your session is about to expire
← Back to Search
Combination Immunotherapy for Small Bowel and Colorectal Cancer
Study Summary
This trial is testing a new combination of immunotherapy drugs to see if it can shrink tumors in people with advanced small bowel and colorectal cancers.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 43 Patients • NCT03628716Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the capacity of enrollment for this clinical trial?
"Affirmative. Information on clinicaltrials.gov reveals that the study, which was initially posted on September 22nd 2020, is actively recruiting individuals for participation. Approximately 80 participants must be recruited from a single medical centre."
Has there ever been a similar trial conducted in the past?
"At the present moment, 20 trials for CV301 are currently underway in 332 cities and one nation. This drug was first trialed by ImmunityBio Inc. back in 2014 with 596 participants; since then 12 clinical studies have been finalized."
Have any other tests been conducted to assess the efficacy of CV301?
"At present, 20 active trials are underway to analyze CV301 with 3 in the third phase of clinical studies. A majority of these tests are located in Ann Arbor, Michigan however there is a total of 508 sites conducting research for this medication."
Is enrollment for this experiment ongoing at the present moment?
"The clinicaltrials.gov website suggests that this research protocol is still actively seeking patient involvement, with first postings on September 22nd 2020 and a recent edit done on November 17th 2022."
How would you rate the potential hazard of CV301 for patients?
"Our experts at Power rate the safety of CV301 as a 2 due to the absence of clinical data that supports its efficacy, despite some evidence pointing towards this drug's security."
What aims are researchers striving to achieve with this clinical experiment?
"This clinical trial, spanning roughly a year's time period, is primarily measuring overall response rate (ORR) for the Triple Therapy. Secondary outcomes encompass Hospitalization Due to PD AEs, Overall Survival and Safety of Quadruple Therapy respectively defined as ratio of participants that are hospitalized due to adverse events attributed to disease progression; assessment of survival per treatment assignment; evaluation of safety combination involving CV301, N-803, M7824 and NHS-IL12 in subjects with advanced small bowel and colorectal cancers."
Share this study with friends
Copy Link
Messenger